US Head and Neck Cancer Market

ID: MRFR/MED/16422-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026
US Head and Neck Cancer Market Research Report: Size, Share, Trend Analysis By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Cancer Type (Oral Cancer, Laryngeal Cancer, Nasopharyngeal Cancer, Throat Cancer, Salivary Gland Cancer), By End Users (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers) and By Diagnosis Method (Biopsy, Imaging Techniques, Endoscopy, Physical Examination) - Growth Outlook & Industry Forecast 2025 To 2035
US Head and Neck Cancer Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.59%
2024 Market Size$ 308.7 Million
2025 Market Size$ 329.04 Million
2035 Market Size$ 622.9 Million
Key Players
Merck & Co
Bristol-Myers Squibb
Roche
Amgen
Eli Lilly and Company
AstraZeneca
Trends
  • Emergence of Targeted Therapies
  • Increased Focus on Early Detection
  • Integration of Telemedicine
Opportunities
  • Rising Incidence Rates
  • Increased Awareness and Education
  • Advancements in Surgical Techniques
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Type (USD Million)
      1. 4.1.1 Surgery
      2. 4.1.2 Radiation Therapy
      3. 4.1.3 Chemotherapy
      4. 4.1.4 Targeted Therapy
      5. 4.1.5 Immunotherapy
    2. 4.2 Construction, BY Cancer Type (USD Million)
      1. 4.2.1 Oral Cancer
      2. 4.2.2 Laryngeal Cancer
      3. 4.2.3 Nasopharyngeal Cancer
      4. 4.2.4 Throat Cancer
      5. 4.2.5 Salivary Gland Cancer
    3. 4.3 Construction, BY End User (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Cancer Research Institutes
      3. 4.3.3 Ambulatory Surgical Centers
    4. 4.4 Construction, BY Diagnosis Method (USD Million)
      1. 4.4.1 Biopsy
      2. 4.4.2 Imaging Techniques
      3. 4.4.3 Endoscopy
      4. 4.4.4 Physical Examination
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Merck & Co (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Amgen (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Eli Lilly and Company (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AstraZeneca (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Novartis (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Pfizer (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY CANCER TYPE
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CONSTRUCTION, BY CANCER TYPE, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY CANCER TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 CONSTRUCTION, BY END USER, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
    18. 6.18 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY CANCER TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
      4. 7.2.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Head and Neck Cancer Market Segmentation

US Head and Neck Cancer Market By Type (USD Million, 2025-2035)

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

US Head and Neck Cancer Market By Cancer Type (USD Million, 2025-2035)

  • Oral Cancer
  • Laryngeal Cancer
  • Nasopharyngeal Cancer
  • Throat Cancer
  • Salivary Gland Cancer

US Head and Neck Cancer Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Cancer Research Institutes
  • Ambulatory Surgical Centers

US Head and Neck Cancer Market By Diagnosis Method (USD Million, 2025-2035)

  • Biopsy
  • Imaging Techniques
  • Endoscopy
  • Physical Examination

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.